(Date:11/24/2009)... REYKJAVIK, Iceland, November 24 /PRNewswire-F... today announced the approval of all of its,"first... District of Delaware,(the "Bankruptcy Court"). de...ef under Chapter 11 of the United States Bankruptc...rders issued by the Bankruptcy Court allow the com...
(Date:11/24/2009)...NGHAI, Nov. 24 /PRNewswire-Asia/ -- Shanghai Biola...inistration (SFDA) has approved the,investigationa...project,(Nodlin), an innovative insulin formulatio...axy to initiate its first phase I clinical study. ...f high blood glucose and poor,metabolism. The comp...
(Date:11/24/2009)...y efficacy endpoint has been met for patients with...r, , QUEBEC CITY, Nov. 24 /PRNewswire-FirstCa...AEZ) (the "Company"), a global biopharmaceutical c...today announced positive efficacy data from a Phas...ugate, AEZS-108 (formerly AN-152), in patients wit...
(Date:11/24/2009)...O, Nov. 24, 2009 Arena P...today that the company is scheduled to present at ...ce on December 1, 2009 at 11:30 a.m. Eastern Time ...tel in New York City. Jack Lief, Arena,s President...ide an overview of the company, including its clin...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3...CALGARY, Oct. 3 /PRNewswire-FirstCall/ - Dr. Brad ...Inc. (TSX: ONC, NASDAQ: ONCY), will present a,corp...ioPartnering Europe,conference in London, U.K. on ...e held at the Queen Elizabeth II Conference Centre...Inc. Oncolytics is a Calgary-based biotechnology ...
...NEW CANAAN, Conn., Oct. 3 Marshall Edwards,Inc. (...orum 2007 at the San,Francisco Palace Hotel on Thu...ll Edwards, Inc. Marshall Edwards, Inc. (Nasdaq: ...n the clinical development of novel anti-cancer th...gy platform which has generated a,number of novel ...
...,Collaboration, Key to Success, EL SEGUNDO, Calif...eaders" have specific characteristics that positio... fifth annual Global Survey of,Supply Chain Progre...),Supply Chain Management Review and Michigan Stat...y chain professionals in 21 industries,identifies ...
Other Biology Technology:Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe 2Marshall Edwards, Inc. to Present at BIO Investor Forum 2007 2Marshall Edwards, Inc. to Present at BIO Investor Forum 2007 32007 Global Survey Identifies Characteristics of Supply Chain Leaders 22007 Global Survey Identifies Characteristics of Supply Chain Leaders 32007 Global Survey Identifies Characteristics of Supply Chain Leaders 4Donkey Serum from CHEMICON
Varian Fluorescence Biomelt from Varian, Inc.
... Green reagent (F-2902) was developed in collabora... permit measurement of the kinetics of Fc receptor...tive burst directly in the phagovacuole.2 The Fc O...um albumin (BSA) that has been covalently linked t...
...00+kb), fosmid (40kb), and large plasmid insert (1...he BAC vector. On command 20-50 fold copy amplific...ification. Available with blue-white screening (pE...or the highest insert stability. Kits include elec...
Biology Products: